“Great news!” was the reaction of one SMA News Today columnist to word of a first gene therapy, Zolgensma, being…
Grace Frank
Grace served as editor-in-chief for BioNews from June 2016 to June 2019 before returning to editing. A longtime newspaper editor and reporter, she was a Pulitzer Prize nominee for an investigative series into eye surgeries wrongly conducted outside a clinical trial. She holds a master’s degree in international relations from the University of Chicago and a bachelor's degree in political science from Rutgers University. Grace lives in France with her extended people-and-pets family.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Grace Frank
The National Institute for Health and Care Excellence (NICE), the U.K. agency that decides on the cost-effectiveness of therapies for inclusion…
AveXis, which is running a series of pivotal clinical trials testing a gene therapy in babies and children with…
Spinal muscular atrophy (SMA) patients in the European Union will soon have access to Spinraza (nusinersen), the first treatment approved…
Motor milestones — a mark of life quality and potential longevity — are evident in a majority of infants with type 1 …